Loading stock data…
CMMB
$1.61+0.14 (+9.40%)
Market ClosedLast close May 1
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Chemomab Therapeutics Ltd. in the Healthcare sector is trading at $1.61. The stock is currently near its 52-week low of $1.35, remaining 34.9% below its 200-day moving average. Technical signals show neutral RSI of 41 and bearish MACD signal, explaining why CMMB maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.61
Potential Upside
5%
Whystock Fair Value$1.69
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal anti...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.76M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-72.93%
Volume
Today's trading volume
42,774
Recent News
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
Alkermes inks $2.1B deal to acquire Avadel, adding the latter's Lumryz and new growth potential to its portfolio.
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
Sanofi's efdoralprin alfa meets all key endpoints in a global phase II study, showing potential as a first restorative recombinant therapy for AATD.
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
VTRS acquires Aculys Pharma to boost its CNS portfolio in Japan, gaining rights to pitolisant and Spydia for narcolepsy and seizure management, respectively.
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.